NEW YORK (GenomeWeb News) – Protagen today said that Bayer HealthCare will evaluate the firm’s UNIarray technology for discovering biomarkers for patient stratification and predictive diagnosis of atrial fibrillation.
 
Protagen’s UNIarray is designed to help develop diagnostics based on indication-specific autoantibody patterns in blood samples. The firm said that such autoantibody patterns are present not only in several autoimmune diseases but also in cancer, neurodegenerative disorders, and some healthy individuals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.